🔗 Share this article

Ministers and senior MPs have expressed alarm that the United Kingdom's recent agreements with the US administration are "lacking a solid foundation." This follows revelations that a recently announced deal on pharmaceutical tariffs, which pledges zero tariffs in exchange for the NHS increasing its costs, lacks any formal legal text beyond broad headline terms published in government press releases.

A Deal Without Detail

The arrangement concerning medicines, described as a "generational" achievement, is still an "statement of intent" without formal ratification. Critics have noted that the press releases from the UK and US governments describe the deal in divergent terms. The British version celebrates securing "duty-free access" as a singular success, while the American announcement highlights the commitment for the NHS to pay significantly more for new medications.

"We face a genuine possibility that the UK government has promised concessions to raise drug prices in return for nothing more than a pledge from President Trump," stated David Henig, a trade expert. "It is documented he has a record of not keeping promises."

Broader Instability and a Paused Tech Deal

Anxieties have been heightened by Washington's move to put on ice the high-value digital accord, which was previously called "a huge leap forward" in the bilateral relationship. The US cited a insufficient movement from the UK on reducing other tariffs as the reason for the pause.

Additionally, concessions promised for British farmers as part of an earlier tariff deal have still not been formally signed off by the US, despite a imminent January deadline. "We have been informed that that the US has not finalized the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Uncertainty Among Officials

Privately, ministers have voiced worries that the government's agreements with the US are unstable and unpredictable. One minister reportedly said the series of agreements as "resting on shaky ground," while another framed the situation as the "current reality" in the transatlantic relationship, marked by "increased uncertainty and instability."

Layla Moran, a senior MP on the health committee, remarked: "The only thing more surprising than Trump's temper tantrums is the UK government's naive belief that his administration is a trustworthy negotiator. The NHS is of vital importance."

Government Downplays Risks, Points to Gains

Officials have downplayed the chances of the US reneging on the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been lobbying for the agreement, desiring stability on imports and pricing, making it more concrete than the paused tech deal.

Officials acknowledge that volatility is part and parcel of dealing with the Trump administration. However, they maintain that the UK has secured concrete outcomes for businesses, such as reduced duties on automobiles compared to other nations. "Our achievement of 25% steel tariffs, which is lower than the rate for the rest of the world, is a solid gain," one official said.

Nevertheless, delays have arisen in enacting the initial US-UK accord. Promised reciprocal agricultural allowances have failed to be approved, and the pledge to "eliminate duties on UK metals" has is still pending, with tariffs remaining at 25%.

Moving forward, the two sides have planned to recommence talks on the paused tech prosperity deal in January, following what were described as "productive" meetings between UK and US officials in Washington.